Modulari-T
modularit.bio
Actively hiring
Regenerative Medicine
Cell & Gene Therapy
Biotechnology
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Team
51-200
employees, estimated range
Backers
2
Y Combinator, Metaplanet
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jan 2023
Went through Y Combinator
Tractionpublic signals, read monthly
Web presence
top 6%
of 133.2M domains by links, Common Crawl
Backed byfrom the funds' portfolios and accelerator catalogs
Y Combinator 
Metaplanet Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Coding Bio unites a high throughput wet lab and ML platform to screen, build, and deliver fully-assembled modular therapies like CARs and…
CellBri's automated cell processing systems simplify manufacturing, reduce risk, and accelerate your path to clinic. Modular or all-in-one…
CRISPR-mediated viral immunity. Designed by nature, harnessed by Ancilia.
Cancer immunotherapy that turns cancer cells into biofactories minting their own destruction.
Our modular engineering platform allows us to create optimized Tregs phenotypes tailored to address a wide variety of autoimmune…
Our Adenovo™ platform and 100-million-variant library move us from discovery to impact. With THEO-260 as our lead programme, our…
Overview
The Modulari-T science is two technologies in one system. MARC - Modular Actuation Receptor Complex and MoVe - Modular Vector.
News
Modulari-T Biosciences Names Tanya E. Borsuk, PhD, as Chief Executive Officer
MONTREAL & HIGHLAND PARK, N.J., April 21, 2026--Modulari-T Biosciences, a biotechnology company pioneering next-generation in vivo cell and gene therapies, today announced the appointment of Tanya E. Borsuk, PhD, as Chief Executive Officer. Co-founder and
Read more
Report
Modulari-T Biosciences Names Tanya E. Borsuk, PhD, as Chief Executive Officer
MONTREAL & HIGHLAND PARK, N.J., April 21, 2026--Modulari-T Biosciences, a biotechnology company pioneering next-generation in vivo cell and gene therapies, today announced the appointment of Tanya E. Borsuk, PhD, as Chief Executive Officer. Co-founder and
Read more
Report